文献速递流行病学与生物统计组学、生物样本库与精准医学

通过多重检验识别和推断随机对照试验中生存结局的疗效差异亚组

Identification and inference for subgroups with differential treatment efficacy from randomized controlled trials with survival outcomes through multiple testing.
PubMed 文献 · Stat Med · 2021-09-20

针对具有时间-事件结局的随机对照试验,提出一种同时推断方法,通过构建对比的同时置信区间控制标记内和标记间多重性,识别具有差异疗效的亚组。基于真实基因型数据的模拟评估了方法性能,并应用于AREDS试验,在包括14号染色体ESRRB-VASH1在内的多个基因区域识别出疗效差异亚组,并在AREDS2试验中验证了靶向和非靶向亚组的一致差异治疗反应。

要点

  • 该方法通过对比的同时置信区间控制标记内和标记间多重性,识别生存结局的疗效差异亚组。
  • 应用于AREDS试验,在多个基因区域(包括14号染色体ESRRB-VASH1)识别出疗效差异亚组。
  • 在独立的AREDS2试验中验证了从AREDS识别的靶向和非靶向亚组具有一致的差异治疗反应。

核心结论

  • 基于多重检验的同时推断方法可自信地识别和推断现代药物开发中的疗效差异亚组。

研究设计与样本

  • 方法学研究,提出同时推断程序,通过对比构建同时置信区间以控制标记内和标记间多重性。
  • 使用真实基因型数据进行模拟评估方法在不同场景下的性能。
  • 应用于AREDS随机对照试验,评估抗氧化剂和锌联合延迟AMD进展的疗效,并在AREDS2试验中验证。

主要发现

  • 在AREDS中识别出多个基因区域(包括14号染色体ESRRB-VASH1)的亚组显示差异疗效。
  • 在AREDS2中,从AREDS识别的靶向和非靶向亚组发现一致的差异治疗反应。

临床怎么用

  • 该同时推断方法可用于具有时间-事件结局的随机对照试验中识别疗效差异亚组,支持精准医学决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the uptake of targeted therapies, instead of the "one-fits-all" approach, modern randomized controlled trials (RCTs) often aim to develop treatments that target a subgroup of patients. Motivated by analyzing the Age-Related Eye Disease Study (AREDS) data, a large RCT to study the efficacy of nutritional supplements in delaying the progression of an eye disease, age-related macular degeneration (AMD), we develop a simultaneous inference procedure to identify and infer subgroups with differential treatment efficacy in RCTs with time-to-event outcomes. Specifically, we formulate the multiple testing problem through contrasts and construct their simultaneous confidence intervals, which appropriately control both within- and across-marker multiplicity. Realistic simulations are conducted using real genotype data to evaluate the method performance under various scenarios. The method is then applied to AREDS to assess the efficacy of antioxidants and zinc combination in delaying AMD progression. Multiple gene regions including ESRRB-VASH1 on chromosome 14 have been identified with subgroups showing differential efficacy. We further validate our findings in an independent subsequent RCT, AREDS2, by discovering consistent differential treatment responses in the targeted and non-targeted subgroups identified from AREDS. This multiple-testing-based simultaneous inference approach provides a step forward to confidently identify and infer subgroups in modern drug development.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Wei Y, Hsu JC, Chen W, et al. Identification and inference for subgroups with differential treatment efficacy from randomized controlled trials with survival outcomes through multiple testing. Stat Med. 2021. PMID: 34542190. doi:10.1002/sim.9196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。